

REVIEW

Open Access

Clinical peculiarities of tuberculosis

Paola Piccini¹, Elena Chiappini¹, Enrico Tortoli¹, Maurizio de Martino², Luisa Galli^{2*}

Abstract

The ongoing spread of tuberculosis (TB) in poor resource countries and the recently increasing incidence in high resource countries lead to the need of updated knowledge for clinicians, particularly for pediatricians. The purpose of this article is to provide an overview on the most important peculiarities of TB in children. Children are less contagious than adults, but the risk of progression to active disease is higher in infants and children as compared to the subsequent ages. Diagnosis of TB in children is more difficult than in adults, because few signs are associated with primary infection, interferon-gamma release assays and tuberculin skin test are less reliable in younger children, *M. tuberculosis* is more rarely detected in gastric aspirates than in smears in adults and radiological findings are often not specific. Treatment of latent TB is always necessary in young children, whereas it is recommended in older children, as well as in adults, only in particular conditions. Antimycobacterial drugs are generally better tolerated in children as compared to adults, but off-label use of second-line antimycobacterial drugs is increasing, because of spreading of multidrug resistant TB worldwide. Given that TB is a disease which often involves more than one member in a family, a closer collaboration is needed between pediatricians and clinicians who take care of adults.

The aim of this review is to provide updated knowledge on childhood tuberculosis (TB), emphasizing the peculiarities in transmission, natural history, clinical features, diagnosis and treatment of TB in children. Knowledge of clinical peculiarities of pediatric TB is now very important because of its ongoing spreading in poor resource countries and its recently increasing incidence in high resource countries [1,2]. This event has been associated to immigration of individuals from high-endemic areas (such as Asia, Africa, South America and Eastern Europe) to low-endemic countries (i.e. Western Europe and United States), as well as to lack of surveillance systems in low-endemic countries in the last decades. On the other hand, improved diagnostic strategies in high resource countries favour early TB recognition in children. The World Health Organization (WHO) estimated that 8.7 million cases of TB occurred worldwide in 2011 [3]. Most of the TB cases in 2011 occurred in Asia (59%) and Africa (26%).

A smaller number of cases are reported in the Eastern Mediterranean region (7.7 %), in the European region (4.3%) and in the region of the Americas (3%). It is

estimated that pediatric cases account for 10-15% of the global TB cases and that the majority of them occur in infants and children under the age of 5 years [3,4]. Despite the importance of pediatric TB, there is very little information about the epidemiology of TB in children worldwide, since WHO data concerns only smear-positive children [5,6].

Differences in transmission

It has long been reported that children with TB are less contagious than adults, because they often have a paucibacillary disease, are less likely to have cavitory lesions in lungs and have a less forceful cough as compared to the subsequent ages [7-9]. Singh *et al.* reported the prevalence of TB infection in children who, in their household, came into contact with adults with pulmonary TB disease and shown a significant difference in contagiousness between smear-positive patients and smear-negative ones [9]. Transmission occurred globally in 95 out of 281 children (33.8%), of which 65 (68.4%) were contacts of sputum-positive adults whereas only 30 (31.6%) were contacts of sputum-negative ones [9]. The rate of TB transmission from smear-positive adults seems to be very high (from 40 to 60%), even if TB transmission from smear-negative subjects with active TB has been clearly documented [10-14]. A limited number of studies

* Correspondence: luisa.galli@unifi.it

²Department of Health Sciences, Meyer Children University Hospital, University of Florence, Florence, Italy
Full list of author information is available at the end of the article

Table 1 Transmission rate of tuberculosis from pediatric index cases[15-25]. n.a. = not available

Index case (age/smear)	Transmission rate to pediatric contacts n (%)	Transmission rate to adult contacts n (%)	Transmission rate to contacts n (%)	Reference
9 years Smear positive	n.a.	n.a.	56/27 (20%)	Curtis et al, 1999 [20]
7 years Smear positive	22/169 (13%)	19/49 (38,7%)	41/218 (18,8%)	Cardona et al, 1999 [21]
4 months Smear positive	0/44 (0%)	1/142 (0,7%)	1/186 (0,5%)	Ciofi degli atti et al, 2011 [25]
7 years Smear positive	1/16 (6,7%)	4/211 (1,9%)	5/227 (2,2%)	Lee et al, 2005 [22]
10 years n.a.	21/29 (72,4%)	n.a.	21/29 (72,4%)	Molicotti et al, 2008 [23]
16 years Smear positive	67/765 (8,7%)	0/172 (0%)	67/937 (7,1%)	Caley et al, 2010 [18]
9 years Smear negative	85/200 (42,5%)	n.a.	85/200 (42,5%)	Paranjothy et al, 2008 [19]
4 months Smear positive	n.a.	n.a.	17/525 (3,2%)	Reynolds et al, 2006 [24]
15 years Smear positive	58/559 (10,3%)	7/67 (10,4%)	65/626 (10,3%)	Phillips et al, 2004 [15]
13 years Smear positive	195/486 (40%)	12/40 (30%)	207/526 (39,3%)	Sacks et al, 1985 [16]
15 years Smear negative	20/52 (37,7%)	0/15 (0%)	20/67 (29,8%)	Baghaie et al, 2012 [17]

reporting rates of *M. tuberculosis* transmission from a pediatric case index are available in literature (Table 1) [15-25]. Most of these involve adolescents and describe school outbreaks [15-19]. The rate of TB transmission to contacts of smear positive adolescents varies from 7 to 39% [15,16,18] whereas transmission to contacts of smear positive younger children (7-10 years old) goes from 2 to 20% [20-22]. Only Molicotti *et al.* described an high risk of TB transmission from a child aged 10 years, founding an interferon-gamma release assay (IGRA) positive in 21 (72%) of 29 contacts [23]. However, the limited number of contacts in this report and lack of information on microscopy on respiratory specimens from the source case do not add consistent data to this issue. Few reports are available if the source case is a young child and they involve infants in hospital, accounting for a transmission rate from infants of 0-3% [24,25]. No data were available about transmission rates from sputum-negative children, but two recent reports from Paranjothy *et al.* and Baghaie *et al.* showed an extensive transmission from two smear negative children aged 9 and 15 years, showing that transmission of *M. tuberculosis* from smear-negative children is possible [17,19]. However it is not clear if contacts involved in these reports have some other risk factors for TB, for example being household contacts of adults with TB [18,20].

Finally, a recent systematic review by Roberts *et al.* came to the conclusion that transmission to close

contacts in school outbreaks are higher if the source case is a child 3 to 11 years of age rather than an adult [10]. In summary, since details on children's own risk factors and type and duration of contact with the source case are lacking in the majority of these reports, further studies are necessary to elucidate contagiousness of young children in the community.

Clinical peculiarities

Natural history

Infection with *M. tuberculosis* can lead to a variety of outcomes which are generally different in children and adults. In the pediatric age the time between infection and the development of symptomatic disease is often very short. Without an adequate treatment, the risk of progression to active disease has been estimated to be higher in infants (30-40% in those younger than 1 year of age) and children (24% in 1-5 years of age) as compared to the subsequent ages. The risk of progression increases again in adolescence (15%), whereas in adults is about 5-10% [6]. Following the inhalation of *mycobacteria*, innate immunity controls infection in immune-competent patients. Tubercle bacillus initially lodges in the lungs and immunity prevents dissemination. The enlarged regional lymph node on chest radiograph, which may be associated with Ghon focus, is the hallmark of primary TB. In this phase children are often asymptomatic or have unspecific respiratory signs.

Tubercle bacillus can multiply and the infection can progress to a caseating lesion and mycobacteria can spread, leading to haematogenous dissemination (meningitis or miliary disease). This occurs more often in infants and young children than in immune-competent adults [26,27]. Children are in fact prone to develop extra-pulmonary TB; about 4% of children infected under the age of 5 years, in fact, develop tubercular meningitis or miliary TB [27].

Latent TB infection (LTBI)

LTBI is a very old definition, introduced in 1909 from von Pirquet who observed positive tuberculin reactions in children who did not have any TB clinical features [28]. Since that time, LTBI indicates a subject with TB infection without progression to active TB. Accordingly to international guidelines LTBI is therefore commonly diagnosed in asymptomatic children who have a normal chest X-ray (or with evidence of healed infection) and a positive tuberculin skin test (TST) or IGRA result [29,30]. Most guidelines, in the past, recommended to consider positive any TST result ≥ 10 mm diameter (or any result ≥ 5 mm if recently exposed to TB or immunocompromised), independently from vaccination with BCG. Recently, at the light of new evidences, UK guidance on TB recommend to consider a TST positive if induration is ≥ 6 mm diameter for non vaccinated and ≥ 15 mm for Bacille Calmette-Guerin (BCG) vaccinated subjects [30]. Moreover, recently, the concept of LTBI has been partially revised. LTBI was considered to be associated with a low number of dormant mycobacteria and the subject was considered to be infected, but not ill nor infectious. There are now some evidences that LTBI is a quite complex clinical condition, with a dynamic equilibrium between latency (characterized by absence of mycobacterial replication) and active disease [31]. This may be particularly true in childhood when, in recently exposed children, the boundary line between primary TB and LTBI may be hardly defined.

Pulmonary tuberculosis

Pulmonary TB includes intrathoracic lymphadenopathy and parenchymal disease. In children, the infection in the lung is often characterized by a Ghon focus with regional lymphadenitis, called "primary complex". Primary TB can rapidly progress, especially in younger children, to lung tissue destruction and a caseating cavity formation (progressive primary TB). Instead in adults, active pulmonary TB more frequently represents a secondary reactivation of a latent TB infection [32]. Primary focus is subpleural in 70% of cases and in 25% of cases the foci are multiple. The lesions usually affect the lobes with greatest ventilation, i.e. the right upper and middle and the left upper lobe [33]. Children can

develop a lobar pneumonia and the colliquative necrosis of the lung parenchyma may lead to the formation of a cavity. Calcifications in children are not commonly seen on chest X-rays. The presence of calcifications indicates that the lesion has been present for at least 6-12 months [34,35]. Pleural involvement may be due to a direct spread of caseous materials from a subpleural lesion or lymph nodes [32], but it is also thought to be the result of a hypersensitivity reaction to mycobacterial antigens. Detection of *M. tuberculosis* in pleural fluid is therefore possible in only about 56% of children with TB, but biopsy of pleural tissue has a higher culture yield [35]. Pleural TB is uncommon in children under the age of 6 years, and it is rare in those younger than 2 years of age; instead, it has commonly been observed in adolescents [32,36]. The most common clinical features of pulmonary TB in young children are non productive cough, low fever and, in rare cases, weight loss. Wheezing, which is usually secondary to extrinsic compression by hilar lymphonodes or even to lumen reduction by endobronchial granulomas, may occur particularly in younger children because of the small airways caliber [37]. An unusual clinical finding, especially in low resource countries, is croup, due to a laryngeal TB with granulation tissue of the glottis. The infection of the glottis can be either due to the direct spread from the bronchus to the larynx or to hematogeneous spread [38]. Gie *et al.* reported that among 354 children initially suspected of suffering from TB, 71 (20%) were found to have other pulmonary diseases such as pneumonia (29%), bronchopneumonia with wheezing (18%) and asthma with lobar or segmental collapse (12%) [37].

Radiological evidences of pulmonary TB in children are less specific than in adults [39]. Adult type disease is distinguished by cavitation that occurs predominantly in the lung apices, in the posterior segment of the upper lobes and in the superior segments of the lower lobes. In younger children the most common radiological findings are non specific lesions and the most typical feature is hilar or paratracheal lymphadenopathy [40]. Adult type disease may occur in adolescents, who usually develop it within 2 years after primary infection [39]. A study carried out in Nigeria investigated the radiological features of TB in 423 patients including 47 children. The most common radiological features in adults were cavitory formations, streaky opacities and nodular opacities, whereas the most common findings in children were hilar lymphadenopathy, bronchopneumonia and pleural fluid collections [40]. The enlargement of lymph nodes is not often visible in chest X-ray, partially because of the presence of the thymus, and the chest X-ray may appear normal. A recent study carried out in asymptomatic children with TB infection has reported that the frequency of chest X-ray abnormalities was only 1,8% [41]. Therefore,

differential diagnosis between active and latent TB are not always easy and a computed tomography (CT) scan with contrast may often be helpful. Enlarged lymph nodes may be detected by CT scan in 60% of children with normal finding on chest X-ray [42].

Tubercular lymphadenitis

The most common manifestation of extrapulmonary TB in the pediatric age is tubercular lymphadenitis. This is part of the primary complex and in children it usually develops within 6 months from infection [27]. More common than in adults, the enlargement of regional lymph nodes as result of TB usually occurs in response to a pulmonary focus within their drainage area and it generally involves cervical, submandibular, supraclavicular, preauricular or submental areas [27,43].

Central Nervous System (CNS) tuberculosis

The most severe manifestations of extra-pulmonary TB in children, as well as in adults, are those occurring in the CNS. Tubercular meningitis (TBM) is more common in early childhood, whereas tuberculoma is usually (but not exclusively) found in older children and adults. Uysal *et al.* recently reported that, excluding the lymph nodes, the most commonly involved site in childhood extra-pulmonary TB is the CNS [44]. Even with anti-tubercular therapy, TBM short-term mortality is high, ranging from 20 to 69% with permanent neurological sequelae occurring in 50% of cases [45,46].

TBM occurs in children more frequently within 2 years of primary infection, predominantly in infants under the age of 5 years [47,48]. The onset is often gradual with non-specific symptoms and diagnosis is consequently difficult. In a recent study conducted in adult and pediatric patients with TBM, the most common

signs and symptoms were headache (69%), fever (69%), nausea/vomiting (61%), anorexia (54%), altered mental state (58%), weight loss (37%), cough (33%) and drowsiness (28%) [49]. Tuberculoma typically occurs in cerebellum in children and in the frontal lobe in adults [27]. The presenting signs are essentially those of a space-occupying lesion: headache, nausea/vomiting and focal neurological signs, and they may differ in children and adults because of the typical different localization of tuberculoma [50-52].

Bone tuberculosis

Bone and joint lesions are more frequent in childhood than in adult age and occur up to 5% of all pediatric TB cases [27]. Skeletal TB usually is a disease of the older child, with the exception of spinal involvement, which can occur even in younger children. The most common manifestations of skeletal TB are osteomyelitis, spondylitis and arthritis [32]. Osteomyelitis can occur in any bone and can be multiple but tuberculous dactylitis and thoracic and lumbar spinal TB (Pott's disease) are the most common manifestations in young children. Pott's disease accounts for up to 40% of bone TB in children, whereas it is rare in adult population [27]. Moreover, vertebral destruction is more severe in children than in adults because bones are mostly cartilaginous [53]. However, *M. tuberculosis* does not produce proteolytic enzymes that can destroy cartilage. Hence there is potential for preservation of good function when early diagnosis is made [27]. Usually immune-competent children have solitary lesions, whereas multiple lesions are common in immune-compromised pediatric patients [32].

All the clinical manifestations listed above are the more frequent ones observed in pediatric TB. Less common manifestations are summarized in Table 2 [53-72]

Table 2 Clinical manifestations of tuberculosis in children [53-72]

Area involved	Clinical presentation
More common	
Lungs and airways	Pneumonia, cavitary lesions, wheezing, laryngeal involvement
Lymph nodes	Enlargement of mediastinal, cervical, submandibular, supraclavicular, preauricular, submental and abdominal lymph nodes
Central nervous system	Meningitis, tuberculoma
Bones and skeletal muscles	Pott's disease, arthritis, cystic of bone, abscess of skeletal muscles
Less common	
Abdomen	Pneumatosis intestinalis, peritonitis, liver and splenic abscess, enterolithiasis, intestinal perforation
Genitourinary tract	Scrotum inflammation, hydrocele, calyceal destruction, ureteral strictures, small-capacity bladder, hydronephrosis, kidney calcification
Heart and vessels	Intracardiac tuberculoma, pseudoaneurysms
Oral cavity	Enlargement of the tonsils, rethropharyngeal abscess, granulomatous cheilitis
Eyes	Uveitis, episcleritis, optic neuritis, orbital tuberculoma
Skin	Scrofuloderma lesions, lupus vulgaris, tuberculosis verrucosa cutis

Diagnostic peculiarities

Diagnosis of TB in children is commonly obtained using the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs), associated to radiological techniques. However, the gold standard for diagnosis of active TB is the detection of *M. tuberculosis* clinical specimens. IGRAs are immunological tests which are based on the important role that interferon-gamma plays in immunological response to *M. tuberculosis*. They are extensively dealt with in a dedicated chapter in this supplement.

Tuberculin Skin Test (TST)

TST available are the Mantoux test and the multi-puncture test, but only the Mantoux test is a standardized method. Hence, the Mantoux test is the preferred test for detecting infection by *M. tuberculosis* and it is currently reported as a synonym of TST. A positive TST reaction is a hallmark of TB infection, but it does not distinguish between latent infection and disease. Tuberculin reactivity usually becomes apparent in 6 weeks, but occasionally can take up to 3 months after infection [73].

False-negative results in adults may occur in patients with immunosuppressive illness, malnutrition, viral infections (such as Human Immunodeficiency Virus infection, influenza, measles and chickenpox) and active disseminated TB. False-negative results in children can be due to the same conditions or only to the young age. Sensitivity is lower in children than in adults. Two recent meta-analysis reported a 80-82% sensitivity of TST in active disease in children [74,75]. By contrast, other authors found a 94% sensitivity in adults [76]. Therefore, after a recent exposure to a source case of TB, a negative TST result does not exclude the diagnosis of TB, particularly in young children. In adults and children who are older than 5 years, a negative result obtained <8 weeks after exposure is considered unreliable for excluding infection and a follow-up test at the end of the window period is therefore necessary. In children under the age of 5 years, the low sensibility of TST and the higher risk of progression of TB infection justify a more timely therapeutic attitude. So far, in this age group, treatment for suspected *M. tuberculosis* infection (window prophylaxis) is recommended also if the initial skin test induration diameter is <5 mm. Only after a second TST administered 8 weeks post-exposure (and absence of clinical and radiological abnormalities) the decision to treat or not to treat is reconsidered [77]. False-positive TST can result from vaccination with (BCG) or after contact with non tuberculous mycobacteria (NTM), since the purified protein derivative (PPD) contains a mixture of over 200 antigens including some antigens common to BCG and NTM [78,79].

Detection of *M. tuberculosis* in sputum or gastric aspirate

The gold standard for diagnosis of active TB is the detection of *M. tuberculosis* in clinical specimens. Sputum microscopy is the most useful test in adults for diagnosis worldwide even though it has a sensitivity of 60% or less, mainly because a positive smear requires at least 5000-10000 acid-fast bacilli (AFB) per μL sputum sample. An added value of smear microscopy, thanks to the semiquantitative score, is its possible use for therapy monitoring. Culture for *M. tuberculosis* takes 8 weeks to be considered negative but following the implementation of liquid media, on average 80% of positive results are reported in less than 20 days. It requires only 10-100 AFB per μL , and can detect pulmonary TB in around 80% of cases [80]. Nucleic acids amplification can provide results within 24-48 hours and performs well on smear-positive specimens with a sensitivity close to 100%; the sensitivity is in contrast suboptimal on smear negative sample [81,82].

Detection of *M. tuberculosis* in sputum is even more difficult in children for at least two reasons. Firstly, as young children are frequently unable to expectorate, a number of procedures have been suggested to obtain samples from the lower respiratory tract. The collection of three consecutive early morning gastric aspirate samples, is widely used with the aim of recovering swallowed sputum for microbiological confirmation in children. A number of less invasive alternative methods have been recently proposed, including induced sputum, nasopharyngeal aspiration and the string test. Secondly, because of the paucibacillary nature of TB disease in children, smears from sputum or from gastric aspirates are positive in less than 15% of children diagnosed with TB and a positive culture is achieved only in less than 40% of cases and even lower is the sensitivity of the nucleic acids amplification [83]. Therefore, investigations in sputum or in gastric aspirate can have a poor performance in identifying active TB in children [84,85]. Microbiological diagnosis of different forms of extrapulmonary TB does not substantially differ in children and adults. Cerebrospinal and lymphonodal are the most frequent extrapulmonary TB localizations in children. The diagnosis of cerebrospinal TB is challenging mainly in consequence of the extremely low number of bacilli due to the limited volume of cerebrospinal sample usually available, its subdivision between multiple tests is often self defeating and the highest sensitivity is achieved using the whole sample for the culture in liquid medium only. The nucleic acid amplification tests too may present reasonable sensitivity, at least with systems accepting large volume of sample (up to 2 mL) [86]. The microbiological diagnosis of lymphonodal TB is not problematic once a proper sample (fine needle aspirate or biopsy) is available. In this case, in particular in presence

of cervico-facial localization, the differentiation of tubercular from non-tubercular etiology is crucial and may be confidently achieved by resorting to methods based on reverse hybridization, which are commercially available.

Because of the increase of drug-resistant TB the susceptibility testing is essential for every newly diagnosed case. The phenotypic test, which is the gold standard, performs well in particular for the major drugs rifampicin and isoniazid; it takes on average two weeks once the strain has grown in culture. In presence of Multi-Drug-Resistant TB (MDR-TB) the antimicrobial susceptibility testing to second line drug is needed; because of standardization problems it should be performed by reference laboratories only. In the last years a number of mutations have been detected which are responsible for resistance to different drugs. The recognition of specific mutations in certain genetic regions is predictive of resistance. Commercially available molecular methods can detect mutations responsible of resistance on strains grown in culture or directly on smear positive clinical specimens. They are able to detect rifampicin resistance in more than 95% of rifampicin-resistant strains [87]. Rifampicin resistance is often considered a surrogate marker of MDR-TB as about 90% of resistant strains are resistant to isoniazid too. Methods suitable to detect mutations responsible of resistance to other drugs are also offered, although very specific, they are characterized by sensitivity clearly lower than that of rifampicin [Table 3].

In summary, there is a need for improved accuracy of the diagnosis of TB in children. In adults smear and sputum culture provide reliable standards because of the diagnosis is usually confirmed microbiologically [66]. In contrast, in children there is a lack of a standardized TB case definition and epidemiological, clinical and radiological findings are always needed to make diagnosis of TB. Some experts in pediatric TB have recently proposed clinical case definition categories (confirmed, possible, probable, unlikely, or not TB) for intrathoracic disease in children. Children with confirmed TB are

those who have at least one sign or symptom suggestive of TB and microbiologically confirmed TB. Children with probable TB are those who have at least one sign or symptom suggestive of TB and a suggestive chest radiography and a positive clinical response to anti-tuberculosis treatment or a documented exposure to *M. tuberculosis* or immunological evidence of *M. tuberculosis* infection. Children with possible TB are those who have at least one sign or symptom suggestive of TB and a suggestive chest radiography or a positive clinical response to anti-tuberculosis treatment or a documented exposure to *M. tuberculosis* or immunological evidence of *M. tuberculosis* infection. Children with unlikely TB are those with only signs or symptoms suggestive of TB. Children in whom TB may be excluded are those without signs or symptoms suggestive of TB and with an alternative diagnosis [88].

Treatment of TB

The recommended treatment regimens for latent and active TB are generally the same for children as for adults. Treatment of latent TB infection is always necessary in children, instead it is not recommended in adults aged more than 36 years because of the increasing risk of hepatotoxicity of drugs with age and because of latent TB in adults is rarely due to a recent infection. Treatment is necessary if adult patients are infected with HIV (because of the major risk of active TB development) or if they are healthcare workers (because of the risk of transmission of *M. tuberculosis* among patients) [89]. Treatment for latent TB involves the use of one or two anti-tubercular agents to prevent the future development of TB disease. Three regimens, containing isoniazid or/and rifampicin, are now recommended for treatment of latent TB in children by the international guidelines [89-93]. Randomized trials have shown that treatment with isoniazid is highly effective, with 90% protection provided by completion of 9 months and 60-80% protection provided by completion of 6 months in adults [90,93]. In children, treatment with isoniazid for 9 months provides protection to approximately 100% . Adverse events associated with isoniazid are generally mild, such as nausea or headache, but can include rashes, hepatitis and peripheral neuropathy. The most serious complication is isoniazid-induced hepatitis, which can progress to fulminant hepatic failure and death [94]. Also treatment with rifampicin for 4 months is recommended in adult population and for 6 months in childhood [89-91]. Although not recommended by all the international guidelines, the 3-month regimen of both rifampicin and isoniazid is often used as alternative regimen in adults and children [90,92]. In a meta-analysis of four small randomized trials, this regime appeared to provide 60% protection in adults but in children data about its effectiveness are not available [94].

Table 3 Gene investigated for mutations responsible of resistance to different drugs and sensitivity percentage of resistant strains presenting mutation in the particular gene [85].

Drug	Gene harbouring mutations	Sensitivity
Rifampicin	<i>rpoB</i>	> 98%
Isoniazid	<i>katG, inhA</i>	80-90%
Quinolones	<i>girA</i>	70-90%
Amikacin, Capreomycin, Kanamycin	<i>Rrs</i>	50-90%
Ethambutol	<i>embB</i>	70-80%

Isoniazid, rifampicin, pyrazinamide and ethambutol are the first-line drugs in the treatment of active TB disease in adults and in children. The most common regime used is a two-month intensive phase of daily isoniazid, rifampicin and pyrazinamide followed by a four-month continuation phase of daily isoniazid and rifampicin. In the first two months, the addition of a fourth drug such as ethambutol or a second-line anti-tubercular drug is necessary in complicated pulmonary TB or in meningeal involvement and, in addition, can protect against the emergence of drug resistant organisms [89].

Ethambutol was not recommended for use in children aged less than 5 years because optic neuritis (the most common form of toxicity which can lead to irreversible blindness) is difficult to monitorize in younger children [95]. Recent studies have shown that ocular toxicity occurs in children taking high or prolonged doses of ethambutol. Thus, if the recommended dosages are adhered to it is now considered safe in children. In fact, a review of Donald *et al.* reported that among 3811 children who had received ethambutol, only two (0,05%) have developed ocular toxicity [83]. Therefore, screening children for ethambutol ocular toxicity seems unnecessary [97].

Until recently, recommended dosages in mg/kg for antitubercular agents in children were deducted from dosages used in adults. Dosages of first-line anti-tubercular drugs in children have been increased in 2009 by WHO, because several pharmacokinetic studies have shown that infants and young children have lower peak serum levels than adolescents and adults, because of a different rate of metabolism, clearance and distribution of drugs [98,99]. This concept has been recently confirmed by Verhagen *et al.* in a pharmacokinetic study coming from Venezuela and involving children younger than 16 years of age [100]. In addition, children tolerate anti-tubercular agents better than adults, partially because of a lower prevalence of underlying liver disease and alcohol usage [101]. A recent study has reported that these doses are safe also in children under the age of two years, in whom few studies on first-line drug pharmacokinetic are available [102]. The doses of first- and second-line anti-tubercular drugs recommended by the most recent international guidelines are listed in Table 4. The incidence of anti-tubercular drug-induced hepatotoxicity has been variably estimated between 2% and 28%, but studies concerning children are limited and include reports in which children and adults are evaluated together [103-105]. A recent review has reported that although anti-tubercular drug-induced hepatotoxicity can occur in children at any age or with any dosage of drugs, the incidence of it is considerably lower than in adults. In fact, among 12,708 children receiving chemoprophylaxis only one case of jaundice

was recorded and abnormal liver functions were documented in 8% of the children studied [101]. In adults, older age seems to be a risk factor for hepatotoxicity, whereas younger children have been reported to be at lower risk [106,107]. However, children with disseminated forms of disease seem to be at greatest risk of anti-tubercular drug-induced hepatotoxicity [101].

However, the emergency of MDR-TB has led to an increase of use of second-line anti-TB drugs and also of drugs with unclear effectiveness against *M. tuberculosis* both in adults and children [108]. Despite the fact that most of these agents were discovered many years ago, information is lacking regarding their pharmacokinetic and pharmacodynamic proprieties, adverse effects and drug interactions in children and therefore they are not formally approved for use in childhood by Food and Drug Administration. Given the increased incident of MDR-TB, to include children in trials of novel or existing agents is now a priority [109]. There are several barriers to include children in TB drugs development: infrequent transmission of TB from children, difficulty of confirming active tuberculosis among children, existent of effective therapy for drug susceptible TB, concerns about pediatric-specific side effects, uncertainties about the appropriate time to involve children in drug development, regulatory requirements engendered by the inclusion of children and concerns about further subdividing the limited resources available for drugs development [110]. Confirmation of MDR-TB may not be possible in children because of the paucibacillary nature of TB and information about the response to treatment of the index case is often needed. In addition, the second-line drugs are not available in pediatric formulations or appropriate table size and therefore dosing may be inaccurate and sub-therapeutic or toxic level are possible. Hence, although their use is often necessary because of the emergence of MDR-TB, carefulness is necessary in off-label use of these medications in children and more studies and multicenter trials should be conducted in children, to test the effectiveness and the safety of anti-tubercular second-line drugs [111]. Seddon *et al.* have recently demonstrated that hearing deficit is common in children treated with aminoglycosides and polypeptides and this can have profound implications for developmental of language. Children should be screened prior to begin treatment and then they should be monitor for hearing at least every month [112]. Ethionamide treatment instead may cause hypothyroidism as in developing children as in adults and the risk is higher for children on regimens including para-aminosalicylic acid and for HIV-infected children [113].

It is also important to note that ensuring compliance to treatment is a major challenge. This is even more true in children, whose major problems are the low

**Table 4 Doses of first- and second-line anti-tubercular drugs recommended in adults and in children [30,93,98,111].
 qd= ones a day; bid= twice a day; tid= three times a day.**

Anti-tubercular drugs	Dosages in adults (mg/kg)	Dosages in children (mg/kg)
First-line anti-tubercular drugs		
Isoniazid	4–6qd	10–15 qd
Rifampicin	8–12 qd	10–20 qd
Pyrazinamide	20–30 qd	30–40 qd
Ethambutol	15–20 qd	15–25 qd
Second-line anti-tubercular drugs		
Capreomycin	15-30 qd	15-30 qd
Kanamycin	15-30 qd	15-30 qd
Amikacin	15-20 qd	15-30 qd
Streptomycin	12-18 qd	20-40 qd
Levofloxacin	7,5-10 qd	7,5-10 qd in children aged > 5 bid in children aged < 5
Moxifloxacin	7,5-10qd	7,5-10 qd
Ofloxacin	15-20qd	15-20 qd
Ethionamide	15-20 qd	15-20 qd
Protionamide	15-20 qd	15-20 qd
Cycloserine	15-20 qd	10-20 qd
Para-amino-salicylic acid (PAS)	150 qd	200-300 qd
Anti-TB drugs with unclear efficacy		
Linezolid	600 qd	10 qd
Clarithromycin	500 bid	7,5 bid
Clofazimine	200qd	1 mg/kg qd
Meropenem	2000 tid	20-40 tid
Amoxicillin/clavulanate	2000/250 bid (maximum dosage)*	40 bid (based on amoxicillin component)*

* Recommended dosage of amoxicillin/clavulanate in adults and children is not clear because of the amoxicillin to clavulanate ratio in commercially available tables and oral suspensions goes from 2:1 to 7:1.

palatability of medications and the daily pill burden. In fact, the daily pill burden can be vast in children because they may require multiple medications due to the few fixed dose drug combinations approved for pediatric age. Hence, good communication between the hospital team, general practitioner or pediatrician, patient and care givers is necessary to make the patient and the family understand that taking the medication is the better option [114].

The differences in treatment of TB between children and adults are summarized in Table 5, where the most important differences in transmission, natural history, clinical features and diagnosis of TB between pediatric and adult age are also listed.

Conclusions

The recently increasing incident of TB in high resource countries has led to a rise of interest in this condition,

particularly by pediatricians, because this finding has been especially observed in children. Hence pediatricians have to deal with an emerging disease, first considered almost disappeared and then little is known about it. In this review we provide information on childhood TB, emphasizing the most important differences in transmission, natural history, clinical features, diagnosis and treatment of TB between children and adults. Infection with *M. tuberculosis* can lead to a variety of outcomes, which are generally different between children and adults, and this confirms the well known concept that “the child is not a small man”.

The knowledge of peculiar clinical features of childhood TB allows a prompt diagnosis and a prompt treatment which are very important for at least three reasons. Firstly, children carry the greatest burden of developing disease and extrapulmonary involvement. In particular, tuberculous meningitis and miliary TB occur

Table 5 Summary of differences in tuberculosis between adults and children.

Category	Adults	Children
Transmission	are frequently contagious because they often have: - cavitary lesions - multibacillary disease - pulmonary tuberculosis - less circumscribed social networks - more forceful cough - productive cough	are infrequently contagious because they often have: - non-cavitary lesions - paucibacillary disease - extrapulmonary tuberculosis - more circumscribed social networks - less forceful cough - non-productive cough
Natural history	- risk of progression is 5-10% - time between primary infection and disease is often long (some years)	- risk of progression is: 45% in infants < 1 year of age; 24% in children 1-5 years of age; 15% in adolescents - time between primary infection and disease is often short (1-6 months)
Clinical presentation	- primary infection is often asymptomatic but symptoms and signs are specific - principally develop pulmonary TB	- primary infection is asymptomatic but it may rapidly progress to symptomatic TB disease with not specific symptoms and signs - often develop extrapulmonary and military TB
Diagnosis	- for screening purposes TST or IGRAs are recommended - detection of <i>M. tuberculosis</i> in sputum smear is achieved in 80% of cases - chest radiography shows cavitary formations	- in children < 5 years of age only TST is recommended because IGRAs may be unreliable - in children ≥ 5 years of age and adolescents TST or IGRAs are recommended - detection in gastric aspirates of <i>M. tuberculosis</i> is achieved in less than 40% of cases - chest radiography shows unspecific lesions (e.g. hilar or mediastinal lymphadenopathy, bronchopneumonia and pleural fluid collections) or may be normal
Treatment	- treatment for latent TB in close contacts should be unnecessary - toxicity induced by anti-tubercular drugs is most common - use of second-line anti-tubercular agents is formally approved - fixed dose drug combinations are available	- treatment for latent TB is always necessary and in close contacts < 5 years it should be started also if TST is negative - toxicity induced by anti-tubercular drugs is less common (also ethambutol is considered safe in young children) - use of second-line anti-tubercular agents is not formally approved - few fixed dose drug combinations are available

TB= tuberculosis; TST= Tuberculin Skin Test; IGRAs = Interferon-gamma Release Assays.

more often in children than in adults. Secondly, they represent the pool from which a large portion of future and contagious cases of adult TB will arise. Finally, because disease in young children reflects recent infection, rather than secondary reactivation as in adults, childhood TB may be considered as a marker of current transmission in the community and therefore the diagnosis of TB in children is also a public health problem and it should always lead to the research of a source case, which, considering that children are rarely contagious, is often an adult.

Despite its importance, prompt diagnosis of TB in children is more difficult than in adults because it is complicated by the low number of signs and symptoms in primary infection, the unreliability of IGRAs in children under the age of 5 years, the lower sensibility of TST in infants than in adolescents and adults, by the more difficult detection of *M. tuberculosis* in gastric aspirates than in sputum-smear in adults and by the non specific radiological findings of primary complex, which is more frequent in children than it is in adults. Hence, further research is needed to develop more sensitive tests for diagnosis of TB in children.

Promptness to make diagnosis allows early treatment with anti-tubercular agents, which greatly improves the

prognosis of patients. Despite the risk of causing major side effects, such as drug-related hepatotoxicity, is less frequent in children than in adults, particular attention is necessary during the follow-up of the young patients to identify any adverse events of anti-tubercular drugs, particularly when they are treated with second-line anti-tubercular drugs for MDR-TB.

Moreover, given that TB is a disease which often involves more than one member of a family from different age groups, a closer collaboration is necessary between pediatricians and clinicians who take care of adults.

Competing interests

the authors declare that have no competing interests

Authors' contributions

PP, collected data from the literature, and drafted the manuscript. EC, ET, MDM and ET conceived the idea helped to draft and critically reviewed the manuscript.

Declarations

Funding for this article came from the Italian Health Ministry /Young Research Project.

This article has been published as part of *BMC Infectious Diseases* Volume 14 Supplement 1, 2014: Highlights in Pediatric Tuberculosis. The full contents of the supplement are available online at <http://www.biomedcentral.com/bmcinfectdis/supplements/14/S1>

Authors' details

¹Emerging Bacterial Pathogens Unit; San Raffaele Scientific Institute, Milan, Italy. ²Department of Health Sciences, Meyer Children University Hospital, University of Florence, Florence, Italy.

Published: 8 January 2014

References

- Center for Disease Control and Prevention: Trends in Tuberculosis - United States, 2012. *MMWR* 2013, **62**:201-205.
- European Center for Disease Control and Prevention: Annual epidemiological report 2012. *Reporting on 2010 surveillance data and 2011 epidemic intelligence data* Stockholm: ECDC; 2013.
- The World Health Organization: **Global tuberculosis report 2012**. Geneva: World Health Organization; 2012.
- Marais BJ, Gie RP, Schaaf HS, Hesselning AC, Obihara CC, Nelson LJ, Earson DA, Donald PR, Beyers N: **The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era**. *Int J Tuberc Lung Dis* 2004, **8**:278-85.
- Walls T, Shingadia D: **Global epidemiology of pediatric tuberculosis**. *J Infect* 2004, **48**:13-22.
- Nelson LJ, Wells CD: **Global epidemiology of childhood tuberculosis**. *Int J Tuberc Lung Dis* 2004, **8**:636-47.
- Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR: **Childhood pulmonary tuberculosis: old wisdom and new challenges**. *Am J Resp Crit Care Med* 2006, **173**:1078-1090.
- Cruz AT, Starke JR: **A current review of infection control for childhood tuberculosis**. *Tuberculosis (Edinb)* 2011, **1**:S11-5.
- Singh M, Mynak ML, Kumar L, Mathew JL, Jindal SK: **Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis**. *Arch Dis Child* 2005, **90**:624-8.
- Roberts JR, Mason BW, Paranjoty S, Parmer SR: **The transmission of tuberculosis in schools involving children 3 to 11 years of age**. *Pediatr Infect Dis J* 2011, **31**:82-4.
- Mtombeni S, Mahomva A, Siziya C, Sanyika C, Doolabh R, Nathoo KJ: **A clinical evaluation of children under the age of five years who are household contacts of adults with sputum positive tuberculosis in Harare, Zimbabwe**. *Cent Afr J Med* 2002, **48**:28-32.
- Totsmann A: **Tuberculosis transmission by patients smear-negative pulmonary tuberculosis in a large cohort in The Netherlands**. *Clin Infect Dis* 2009, **47**:1135-1142.
- Behr MA: **Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli**. *Lancet* 1999, 1135-1142.
- Elwood RK, Cook VJ, Hernandez-Garduno E: **Risk of tuberculosis in children from smear negative source cases**. *Int J Tuberc Lung Dis* 2005, **9**:49-55.
- Phillips L, Carlile J, Smith D: **Epidemiology of a tuberculosis outbreak in a rural Missouri high school**. *Pediatrics* 2004, **113**:e14-9.
- Sacks JJ, Brenner ER, Breeden DC, Anders HM, Parker RL: **Epidemiology of a tuberculosis outbreak in a South Carolina junior high school**. *Am J Public Health* 1985, **75**:361-5.
- Baghaie N, Khalilzadeh S, Bolursaz MR, Parsanejad N: **Contact tracing of a 15-year-old girl with smear-negative pulmonary tuberculosis in Tehran**. *East Mediterr Health* 2012, **18**:399-401.
- Caley M, Fowler T, Welch S, Wood A: **Risk of developing tuberculosis from a school contact: retrospective cohort study, United Kingdom, 2009**. *Euro Surveill* 2010, **15**:1-4.
- Paranjoty S, Eisenhut M, Lilley M, Bracebridge S, Abubakar I, Mulla R, Lack K, Chalkley D, Howard J, Thomas S, McEvoy M: **Extensive transmission of mycobacterium tuberculosis from 9 years old child with pulmonary tuberculosis and negative sputum smear**. *BMJ* 2008, **337**:a1184, doi:10.1136/bmj.a1184.
- Curtis AB, Ridzdon R, Vogel R, McDonough S, Hargreaves J, Ferry J, Valway S, Onorato IM: **Extensive transmission of mycobacterium tuberculosis from a child**. *N Engl J Med* 1999, **34**:1491-5.
- Cardona M, Bek MD, Mills K, Isaacs D, Alperstein G: **Transmission of tuberculosis from a seven-year-old child in a Sydney school**. *J Pediatr Child Health* 1999, **35**:375-8.
- Lee EH, Graham PL, O'Keefe M, Fuentes L, Saiman L: **Nosocomial transmission of Mycobacterium tuberculosis in a children's hospital**. *Int J Tuberc Lung Dis* 2005, **9**:689-92.
- Molicotti P, Bua A, Mela G, Olmeo P, Delogo R, Ortu S, Sechi LA, Zanetti S: **Performance of quantiFERON-TB testing in a tuberculosis outbreak at a primary school**. *J Pediatr* 2008, **152**:585-6.
- Reynolds DL, Gillis F, Kitai I, Deamond SL, Silverman M, King SM, Matlow AG, Crockett M: **Transmission of Mycobacterium tuberculosis from an infant**. *Int J Tuberc Lung Dis* 2006, **10**:1051-6.
- Ciofi degli Atti ML, Castelli Gattinara G, Ciliento G, Lancellata L, Russo C, Coltella L, Vinci MR, Zaffina S, Raponi M: **Prolonged in-hospital exposure to an infant with active pulmonary tuberculosis**. *Epidemiol Infect* 2011, **139**:139-42.
- Griffith-Richards SB, Goussard P, Andronikou S, Andronikou S, Gie RP, Przybojewski SJ, Strachan M, Vadachia Y, Kathan DL: **Cavitating pulmonary tuberculosis in children: correlating radiology with pathogenesis**. *Pediatr Radiol* 2007, **37**:798-804.
- Carroll ED, Clark JE, Cant AJ: **Non-pulmonary tuberculosis**. *Pediatr Respir Rev* 2001, **2**:113-9.
- von Pirquet C: **Frequency of tuberculosis in children**. *J Am Med Assoc* 1909, **52**:675-678.
- American Academy of Pediatrics: **Tuberculosis**. In *Red Book: 2012 Report of the Committee on Infectious Diseases*. 28 edition. Elk Grove Village, IL: American Academy of Pediatrics; Pickering LK, Baker CJ, Kimberlin DW, Long SS 2012.
- Abubakar I, Griffiths C, Ormarod P: **Guideline Development Group. Diagnosis of active and latent tuberculosis: summary of NICE guidance**. *BMJ* 2012, **345**:e6828.
- Gideon HP, Flynn JL: **Latent tuberculosis: what the host "sees"?** *Immunol Res* 2011, **50**:202-12.
- Cruz AT, Starke JR: **Pediatric tuberculosis**. *Pediatr Rev* 2010, **31**:13-25.
- Mandalakas AM, Starke JS: **Current concepts of childhood tuberculosis**. *Semin Pediatr Infect Dis* 2005, **16**:93-104.
- Starke JR, Munoz FM: **Tuberculosis**. In *Nelson Textbook of pediatrics*. 18 edition. Saunders Elsevier; Kliegman RM, Jenson HB, Behrman RE, Stanton BF 2007:1240-1254.
- Kim WS, Moon WK, Kim IO, Lee HJ, Im JG, Yeon KM, Han MC: **Pulmonary tuberculosis in children: evaluation with CT**. *AJR Am J Roentgenol* 1997, **168**:1005-9.
- Chakrabarti B, Davies PD: **Pleural tuberculosis**. *Monaldi Arch Chest Dis* 2006, **65**:26-33.
- Gie RP, Beyers N, Schaaf HS, Nel ED, Smuts NA, van Zyl S, Donald PR: **TB or not TB? An evaluation of children an incorrect initial diagnosis of pulmonary tuberculosis**. *S Afr Med J* 1995, **85**:658-62.
- Lzarus AA, Thilagar B: **Tuberculosis of pericardium, larynx, and other uncommon sites**. *Dis Mon* 2007, **53**:46-54.
- Marais BJ: **Childhood tuberculosis: epidemiology and natural history of disease**. *Indian J Pediatr* 2011, **78**:321-327.
- Ernie SA: **An appraisal of the radiological features of pulmonary tuberculosis in Ilorin**. *Niger Postgrad Med J* 2003, **10**:264-9.
- Lee EY, Tracy DA, Eisenberg RL, Arellano CM, Mahmood SA, Cleveland RH, Zurakowski D, Boiselle PM: **Screening of asymptomatic children for tuberculosis is a lateral chest radiograph routinely indicated?** *Acad Radiol* 2011, **18**:184-90.
- Delacourt C, Mani TM, Bonnerot V, de Blic J, Sayerg N, Lallemand D, Sheimann P: **Computed tomography with normal chest radiograph in tuberculous infection**. *Arch Dis Child* 1993, **69**:430-432.
- Donald PR: **The chemotherapy of tuberculous lymphadenopathy in children**. *Tuberculosis* 2010, **90**:213-224.
- Uysal G, Gursoy T, Guven A, Gunindi F, Cuhaci B: **Clinical features of extrapulmonary tuberculosis in children**. *Saudi Med J* 2005, **26**:270-3.
- Christensen AS, Andersen AB, Thomsen VO, Andersen PH, Johansen IS: **Tuberculous meningitis in Denmark: a review of 50 cases**. *BMC Infect Dis* 2011, **22**:11-47.
- Patayatchi N, Bamber S, Dawood H, Bobat R: **Multidrug-resistant tuberculous meningitis in children in Durban, South Africa**. *Pediatr Infect Dis J* 2006, **25**:147-50.
- Yaramis A, Gurkan F, Elevli M: **Central nervous system tuberculosis in children: a review of 214 cases**. *Pediatrics* 1998, **102**:E49.
- Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM: **Tuberculosis of the central nervous system in children: a 20-year survey**. *J Infect* 2000, **41**:61-68.
- Anderson NE, Somaratne J, Holland D, Thomas MG: **A review of tuberculous meningitis at Auckland city hospital, New Zealand**. *J of Clin Neurosc* 2010, **1018**-1022.

50. Singh DK, Rastogi M, Sharma A, Husain M: **Unilateral hydrocephalus: atypical presentation of intracranial tuberculoma.** *Turk Neurosurg* 2011, **21**:242-5.
51. Tyagi DK, Balasubramanian S, Purandare HR, Savant HV: **Intramedullary tuberculoma in a six years old.** *Neurol India* 2010, **58**:736-8.
52. Yanardag H, Uygun S, Yumuk V, Caner M, Canbaz B: **Cerebral tuberculosis mimicking intracranial tumour.** *Singapore Med J* 2005, **46**:731-3.
53. Zingmout M, Boujraf S, Chakour K, Chaoui Mel F: **Pott's disease in children.** *SurgNeurol Int* 2011, **11**:2-1.
54. Mignone F, Calitri C, Scolfaro C, Garofalo S, Lonati L, Versace A, Tovo PA: **An adolescent with persistent cervical lymphadenopathy and retropharyngeal abscess: case report.** *Minerva Pediatr* 2013, **65**:569-74.
55. Sultana A, Bhuiyan MS, Haque A, Bashar A, Islam MT, Rahman MM: **Pattern of cutaneous tuberculosis among children and adolescent.** *Bangladesh Med Res Coun Bull* 2012, **38**:94-7.
56. Shah I, Ranghale A: **Ileal perforation in a child with abdominal tuberculosis.** *Ann Trop Paediatr* 2010, **30**:241-3.
57. Shah I, Uppuluri R: **Clinical profile of abdominal tuberculosis in children.** *Indian J Med Sci* 2010, **64**:204-9.
58. Malaviya AN, Kotwal PP: **Arthritis associated with tuberculosis.** *Best Pract Res Clin Rheumatol* 2003, **17**:319-43.
59. Eren A, Atay EF, Omeroglu H, Altintas F: **Solitary cystic tuberculosis of long tubular bones in children.** *J Pediatr Orthop B* 2003, **12**:72-5.
60. Cantinotti M, De Gaudio M, de Martino M, Assanta N, Moschetti R, Veneruso G, Crocetti M, Murzi B, Chiappini E, Galli L: **Intracardiac left atrial tuberculoma in an eleven-month-old infant: case report.** *MC Infect Dis* 2011, **11**:359.
61. Santos FC, Nascimento AL, Lira LA, Lima JF, Montenegro Rde A, Montenegro LM, Schindler HC: **Bone tuberculosis: a case report on child.** *Rev Soc Bras Med Trop* 2013, **46**:249-51.
62. Bhatt GC, Nandan D, Singh S: **Isolated tuberculous liver abscess in immunocompetent children - report of two cases.** *Pathog Glob Health* 2013, **107**:35-7.
63. Cox SG, Naidoo NG, Wood RJ, Clark L, Kilborn T: **Tuberculous iliac artery aneurysm in a pediatric patient.** *J Vasc Surg* 2013, **57**:834-6.
64. Norazizah MA, Wan Hazabbah WH, Rohaizan Y, Shatriah I: **Isolated optic neuritis secondary to presumed tuberculosis in an immunocompetent child.** *Med J Malaysia* 2012, **67**:102-4.
65. Singal R, Gupta S, Gupta S: **Primary abdominal tuberculosis presenting as peritonitis in a young child-managed surgically.** *Asian Pac J Trop Med* 2012, **5**:413-5.
66. Prasad P, Bhardwaj M: **Primary tuberculosis of tonsils: a case report.** *Case Rep Med* 2012, **2012**:120382.
67. Alp H, Orbak Z, Sepetçigil O, Kantarci M, Kartal I: **Abdominal tuberculosis in a child presenting with radiological evidence of pneumatosis intestinalis and portal venous gas.** *J Health Popul Nutr* 2010, **28**:628-32.
68. Kumar V, Singh AP, Meher R, Raj A: **Primary tuberculosis of oral cavity: a rare entity revisited.** *Indian J Pediatr* 2011, **78**:354-6.
69. Sookpotarom P, Nimanussornkul K, Luecha O, Poolsavatkitikool R, Vejchapipat P: **Isolated tuberculosis of tunica vaginalis in a child.** *Pediatr Surg Int* 2010, **26**:763-5.
70. Tuli N: **Orbital tuberculosis in childhood with intracranial extension: a case report.** *Cases J* 2010, **28**:3-38.
71. Mishra D, Singh S, Juneja M: **Enterolithiasis: An uncommon finding in abdominal tuberculosis.** *Indian J Pediatr* 2009, **76**:1049-50.
72. Nerli RB, Kamat GV, Alur SB, Koura A, Vikram P, Amarkhed SS: **Genitourinary tuberculosis in pediatric urological practice.** *J Pediatr Urol* 2008, **4**:299-303.
73. Shingadia D, Novelli V: **Diagnosis and treatment of tuberculosis in children.** *Lancet Infect Dis* 2003, **3**:624-32.
74. Sun L, Xiao J, Miao Q, Feng WX, Wu XR, Yin QQ, Jiao WW, Shen C, Liu F, Shen D, Shen AD: **Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis.** *FEMS Immunol Med Microbiol* 2011, **63**:165-173.
75. Chiappini E, Accetta G, Bonsignori F, Boddi V, Galli L, Biggeri A, de Martino M: **Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a systematic review and meta-analysis.** *Int J Immunopharmacol* 2012, **25**:557-64.
76. Lee JE, Kim HJ, Sei WL: **The clinical utility of tuberculin skin test and interferon- γ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study.** *BMC infect Dis* 2011, **18**:11-96.
77. National Tuberculosis controllers Association, Centers for Disease Control and Prevention (CDC): **Guidelines for the Investigation of Contacts Persons with Infectious Tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC.** *MMWR Recomm Rep* 2005, **54**:1-47.
78. Fahrat M, Greenaway C, Pai M, Menzies D: **False-positive tuberculin skin tests. What is the absolute effect of BCG and non-tuberculous mycobacteria?** *Int J Tuberc Dis* 2006, **10**:1192-1204.
79. Snider DE Jr: **BacilleCalmette-Guerine vaccinations and tuberculin skin tests.** *JAMA* 1985, **253**:3438-39.
80. Siddiqi K, Lambert ML, Walley J: **Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.** *Lancet Infect Dis* 2003, **3**:288-96.
81. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Ammerman AS: **Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis.** *J Clin Microbiol* 2003, **41**:3233-3240.
82. Center for Disease Control and Prevention: **Update guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis.** *MMWR Morb Mortal Wkly Rep* 2009, **58**:7-10.
83. Bianchi L, Galli L, Moriondo M, Veneruso G, Becciolini L, Azzari C, Chiappini E, de Martino M: **Interferon-gamma release assay improved diagnosis of tuberculosis in children.** *Pediatr Infect Dis J* 2009, **28**:510-514.
84. Starke J, Ong L, Eisenach K: **Detection of M. tuberculosis in gastric aspirates samples from children using polymerase chain reaction.** *Am Rev Respir Dis* 1993, **147**:A801.
85. Smith K, Starke J, Eisenach K, Ong LT, Denby M: **Detection of Mycobacterium tuberculosis in clinical specimens from children using a polymerase chain reaction.** *Paediatrics* 1996, **97**:155-60.
86. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, Pascarella M, Borroni E, Mondo A, Piana F, Scarparo C, Coltella L, Lombardi G, Cirillo DM: **Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis.** *Eur. Respir J* 2012, **40**:442-7.
87. Pai M, Kalantri S, Dheda K: **New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance.** *Expert Rev Mol Diagn* 2006, **6**:423-432.
88. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Haterill M, Hesselring AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, Madhi S, Makhene M, Marais BJ, McNeely DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C: **Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.** *J Infect Dis* 2012, **15**(Suppl 2):S199-208.
89. NICE Guidelines: **CG33 Tuberculosis: Full Guideline.** [http://www.nice.org.uk/guidance/].
90. American Thoracic Society: **Targeted tuberculin testing and treatment of latent tuberculosis infection.** *MMWR Recomm Rep* 2000, **49**:1-51.
91. Public Health Agency of Canada, Canadian Lung Association: **Canadian Tuberculosis Standards.** Ottawa; 2007.
92. Centre for disease Control and Prevention: **Treatment of Latent Tuberculosis Infection (LTBI).** 2010 [www.cdc.gov/tb].
93. The World Health Organization: **Treatment of tuberculosis. Guidelines , 4** 2010 [http://who.int].
94. Ena J, Valls V: **Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.** *Clin Infect Dis* 2005, **40**:670-6.
95. Graham SM: **Treatment of paediatric TB: revised WHO guidelines.** *Pediatr Resp Rev* 2011, **12**:22-26.
96. Donald PR, Maher D, Maritz JS, Qazi S: **Ethambutoldosage for the treatment of children: literature review and recommendations.** *Int J Tuberc Lung Dis* 2006, **10**:1318-30.
97. Jones DH, Russell-Eggitt I: **Is It Necessary to Screen Children for Ethambutol Toxicity? Recommendations for Clinical Surveillance.** Great Ormond Street Hospital for Children, London; 2010.
98. The World Health Organization: **Rapid advice: Treatment of tuberculosis in children.** Geneva; 2010 [http://who.int].
99. McIlleron H, Willemse M, Weryel CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR: **Isoniazid plasma concentrations in a cohort of South African**

- children with tuberculosis: implications for paediatric dosing guidelines. *Clin Infect Dis* 2009, **48**:1547-53.
100. Veraghen LM, Lopez D, Hermans PW, Warris A, de Groot R, Garcia JF, de Waard JH, Aarnoutse RE: **Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.** *Trop Med Int Health* 2012, Epub ahead of print.
 101. Donald PR: **Antituberculosis drug-induced hepatotoxicity in children.** *Pediatr Rep* 2011, **3**:e16.
 102. Thee S, Seddon JA, Donald PR, seifart HI, Weryly CJ, Hesselning AC, Rosenkranz B, roll S, Schaaf HS: **Pharmacokinetics of isoniazid, rifampicin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.** *Antimicrob Agents Chemother* 2011, **55**:5560-7.
 103. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R: **Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.** *J Gastroent and Hepat* 2008, **23**:192-292.
 104. Nolan CM, Goldberg SV, Buskin SE: **Hepatotoxicity associated with isoniazid preventive therapy: a 7 years survey from a Public Health Tuberculosis Clinic.** *JAMA* 1999, **281**:1014-1018.
 105. LoBue PA, Moser KS: **Use of isoniazid for latent tuberculosis in a public health clinic.** *Am J Respir Crit Care Med* 2003, **168**:143-447.
 106. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK: **Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.** *Thorax* 1996, **51**:132-136.
 107. Ohkawa K, Hashiguchi M, Ohno K, Takahashi S, Kondo S, Echizen H, Ogata H: **Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.** *Clin Pharmacol Ther* 2002, **72**:220-226.
 108. Pinon M, Scolfaro C, Bignamini E, Cordola G, Esposito I, Milano R, Mignone F, Bertaina C, Tovo PA: **Two pediatric cases of multidrug-resistant tuberculosis with linezolid and moxifloxacin.** *Pediatrics* 2010, **126**:e1253-6.
 109. Seddon JA, Hesselning AC, Schaaf HS: **Retooling existing tuberculosis drugs for children.** *Clin Infect Dis* 2012, Epub ahead of print.
 110. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR: **Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens.** *PLoS Med* 2008, **5**:e176.
 111. Seddon JA, Hesselning AC, Marai BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS: **Paediatric use of second-line anti-tuberculosis agents: a review.** *Tuberculosis (Edinb)* 2012, **92**:9-17.
 112. Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesselning AC, Schaaf AS: **Hearing loss in children treated for multidrug-resistant tuberculosis.** *J Infect* 2012, Epub ahead of print.
 113. Thee S, Zollner EW, Willemse M, Hesselning AC, Magdorf K, Shaaf HS: **Abnormal thyroid function tests in children on ethionamide treatment.** *Int J Tuberc Lung Dis* 2011, **15**:1191-1193.
 114. Hoskins W: **Paediatric tuberculosis.** *Postgrad Med J* 2003, **79**:272-278.

doi:10.1186/1471-2334-14-S1-S4

Cite this article as: Piccini et al.: Clinical peculiarities of tuberculosis. *BMC Infectious Diseases* 2014 **14**(Suppl 1):S4.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

